Clinical trials: Movement Disorders
Parkinson's Disease
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary…
- Trial name
- 03003MAD (NCT02055274)
- Testing
- LY03003, Neupro
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor
Demonstrate safety and efficacy of TAPS delivered by a Cala device as a treatment for action tremor in subjects with Parkinson's disease hand tremor
- Trial name
- NCT05012579
- Testing
- Cala Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cala Health, Inc.
Parkinson's Disease (PD)
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg…
- Trial name
- NCT02170376
- Testing
- BIA 9-1067, Entacapone, Levodopa/carbidopa
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Absence Epilepsy, Childhood, Absence Seizures
Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings
This study is being done to find out if a smartphone app can identify absence seizures. Children who have a history of absence seizures, as well as children without any seizure history, will be testing out the app.
- Conditions
- Absence Epilepsy, Childhood, Absence Seizures, Absence Epilepsy, Epilepsy in Children
- Trial name
- DASHER (NCT06093490)
- Testing
- Eysz Hyperventilation Recorder
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Eysz, Inc.
Parkinson's Disease
BradyXplore Phase II: Bradykinesia Feature Extraction System
Study objectives are to improve motion sensor algorithms for measuring bradykinesia in the clinic and the home, evaluate test-retest reliability of motion sensor algorithms for measuring bradykinesia compared to clinician raters…
- Trial name
- NCT02358876
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Progressive Supranuclear Palsy
A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy.
- Trial name
- NCT04008355
- Testing
- AZP2006 oral solution
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- AlzProtect SAS
Parkinson Disease, Multiple System Atrophy
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.
- Trial name
- EXIST (NCT06671938)
- Testing
- exidavnemab
- Where
- 7 sites in Poland, Spain
- Volunteers
- 38 people
- Sponsor
- BioArctic AB
Parkinson Disease
A Study of LY03003 in Patients With Early-stage Parkinson's Disease
This study is to characterize the pharmacokinetics and to evaluate the safety as well as tolerability of LY03003 following multiple escalating intramuscular injections
- Trial name
- NCT04044547
- Testing
- Rotigotine, extended-release microspheres
- Volunteers
- 60 people
- Sponsor
- Luye Pharma Group Ltd.
Idiopathic Parkinson Disease
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
- Trial name
- PRO-Go (NCT03944785)
- Testing
- XADAGO (safinamide)
- Where
- 30 sites in United States
- Volunteers
- 164 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
- Trial name
- NCT02847650
- Testing
- PF-06649751
- Where
- 37 sites in United States, France and 2 more
- Volunteers
- 57 people
- Sponsor
- Pfizer
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Bowel Incontinence
A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage
The purpose of this study is to determine whether the use of the Renew Insert is effective, tolerable and safe in the treatment of accidental bowel leakage due to bowel incontinence.
- Trial name
- REST (NCT01475474)
- Testing
- Renew Insert
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Renew Medical
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Tourette's Syndrome
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics.
- Trial name
- NCT02102698
- Testing
- Ecopipam
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emalex Biosciences Inc.
Dyskinesia, Drug-Induced, Parkinson Disease
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
This will be a prospective, multi-center, randomized, double-blind, parallel group, placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic medication and have at least mild levodopa-induced…
- Trial name
- NCT03987750
- Testing
- Safinamide Methanesulfonate 150mg, Safinamide Methanesulfonate 100mg
- Sponsor
- Zambon SpA
Parkinson's Disease
Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study .
- Trial name
- NCT01856439
- Testing
- ProSavin
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Axovant Sciences Ltd.
Multiple System Atrophy
A Biomarker Study of ATH434 in Participants With MSA
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
- Trial name
- NCT05864365
- Testing
- ATH434
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alterity Therapeutics